Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | CCR3 | P51677 | 1/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920778 | 0.88 | ACHE (0.58) | DRD4CCR2ALDH1A1 | |
| SCHEMBL1920767 | 0.87 | SIGMAR1 (0.55) | SIGMAR1DRD4MCHR1CCR3 | |
| SCHEMBL1920596 | 0.87 | TEAD1 (0.54) | SIGMAR1MEN1KMT2ADRD4MCHR1 | |
| SCHEMBL1921353 | 0.82 | MCHR1 (0.59) | SIGMAR1DRD4MCHR1 | |
| SCHEMBL1921568 | 0.78 | SIGMAR1 (0.60) | SIGMAR1KMT2AMCHR1CCR3CACNA1G | |
| SCHEMBL9727102 | 0.78 | SIGMAR1 (0.72) | SIGMAR1MEN1KMT2ADRD4MCHR1 | |
| SCHEMBL7475783 | 0.78 | SIGMAR1 (0.65) | SIGMAR1MEN1KMT2ADRD4MCHR1 | |
| Trifluoroacetic Acid SCHEMBL1921476 | 0.77 | SIGMAR1 (0.55) | SIGMAR1MEN1KMT2AHRH3 | |
| SCHEMBL13202825 | 0.76 | MEN1 (0.67) | SIGMAR1MEN1KMT2ADRD4MCHR1 | |
| SCHEMBL1921313 | 0.75 | SIGMAR1 (0.58) | SIGMAR1MEN1KMT2AMCHR1CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622914-B1 | NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | TROVIS PHARMACEUTICALS LLC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7030240-B2 | 5-HT receptor antagonist; [1-(2-Fluoro-benzyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine; treating vascular disorders, angina, migraine, pulmonary hypertension and systemic hypertension | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | HTR5A, HTR2C, HTR1A | SIGMAR1 1187/4885MEN1 2833/4885KMT2A 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.